Trial Profile
Apatinib as Second-line Treatment of Advanced Pancreatic Cancer, Phase II Clinical Study of Open Arm
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms Apslpanc
- 30 Nov 2016 Status changed from not yet recruiting to recruiting.
- 06 Apr 2016 New trial record